Determination of bupivacaine in human plasma by capillary gas chromatography with nitrogen-selective detection

Normand, Y. Le; Villepoix, C. De; Athouel, A.; Kergueris, Marie‐France; Bourin, Michel; Larousse, C; Blanlœil, Y.; Melchior, J.C.

doi:10.1016/s0378-4347(00)83467-2

Cited by 5 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma concentrations of bupivacaine were determined by capillary gas chromatography on a Shimadzu GC‐17A (Kyoto, Japan) (19,20). The assay was linear to 20 mg·l −1 , sensitive to 0.005 mg·l −1 , with a coefficient of variation of 3.6% at 1 mg·l −1 .…”

Section: Methodsmentioning

confidence: 99%

Plasma concentrations of bupivacaine after combined spinal epidural anaesthesia in infants and neonates

Frawley

Ragg

Hack

2000

Pediatric Anesthesia

View full text Add to dashboard Cite

The unbound and bound plasma concentration of bupivacaine in 50 infants less than 55 weeks postconceptual age was determined following combined spinal and epidural anaesthesia (csea). Plasma concentrations were determined at 15-min intervals up to 60 min postspinal anaesthesia. Maximum plasma bupivacaine levels were recorded between 45 and 60 min post CseA. Total plasma concentrations above a toxic threshold level of 4 microg.ml(-1) were recorded in 4% of patients and above 2.5 microg.ml(-1) in 10% of patients. Unbound bupivacaine levels were greater than a presumed toxic level of 0.25 microg.ml(-1) in 16% of cases and above 0.3 microg. ml(-1) in 14% of cases. A wide range of protein binding was measured (varying from 53.8-98.2%) and could not be correlated with standard indicators of local anaesthetic binding. Two neonates had brief apnoeas in the immediate perioperative phase but no adverse cardiac or central nervous system events attributable to the performance of Csea were demonstrated.

show abstract

Section: Methodsmentioning

confidence: 99%